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for SEC and UST were 6.84, 2.87, € 54,428 and 6.79, 2.08, € 54,572, respectively. 
Probabilistic sensitivity analysis indicated robustness in the Conclusionsof domi-
nance/highly cost-effective approach for SEC vs. UST. ConClusions: Applying 
stricter criteria for response (i.e., PASI≥ 75 instead of PASI≥ 50) for treatment dis/
continuation for highly efficacious PSO therapy (SEC) Resultsin overall greater 
QALYs and cost savings for the health-care system.
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objeCtives: There are limited data on healthcare resource utilisation associated 
with inadequately controlled chronic spontaneous (idiopathic) urticaria (CSU/
CIU) patients. ASSURE-CSU is an observational, multinational study conducted to 
identify and quantify burden of illness in these patients. Data on resource utilisa-
tion for Canada, Germany, UK and the Netherlands are summarised. Methods: 
This study included a 1-year retrospective medical record abstraction and a cross-
sectional patient-reported outcomes survey. Adult CSU/CIU patients with disease 
persisting for ≥ 12 months despite treatment were assessed. Data on resource 
utilisation were extracted from patient medical records, and reported descrip-
tively. Results: Medical records were abstracted for 99 patients each in Canada 
and the Netherlands, 100 in Germany and 83 in the UK. In Canada, 83% patients 
had one or more visits to a health care professional (HCP) with a total mean (SD) 
of 3.1 (2.57) annual visits. In the prior 12 months, visits to allergists and derma-
tologists were reported by 72% and 11% patients. In Germany, 52% patients visited 
HCPs [annual visits: 3.3 (3.81)]. Hospitalisations and emergency room (ER) visits 
were reported by 18% and 15% patients. Allergists and dermatologists were visited 
by 33% and 31% patients. In UK, 86% patients visited HCPs [annual visits: 3.7 (2.68)]. 
Dermatologists were seen by 54% patients, allergists by 30% and hospital nurses 
by 10%. HCPs were visited by 87% patients in the Netherlands [annual visits: 4.1 
(3.87)]. Visits to dermatologists, allergists and other consultants were reported by 
51%, 42% and 13% patients. ER visits and hospitalisations were less frequent in 
Canada, the UK and the Netherlands compared with Germany. ConClusions: 
This is the first study to quantify resource utilisation associated with inadequately 
controlled CSU/CIU. The types of medical resources differ among the countries 
depending on the local healthcare specificities. Resource utilisation pattern was 
primarily outpatient but varied across countries.
SenSory SyStemS diSorderS – Patient-reported outcomes & Patient  
Preference Studies
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objeCtives: Chronic urticaria (CU) (or chronic hives) can be inducible or spontane-
ous (also known as idiopathic urticaria) (CSU/CIU). Data supporting the impact of 
CSU/CIU on patients and comparison with other dermatological diseases are scarce. 
This study evaluated economic burden associated with CU relative to psoriasis (PsO) 
overall and different severity levels of PsO among the adults in 5 European (France, 
Germany, Italy, Spain and UK) countries. Methods: Data from patients diagnosed 
with chronic hives (proxy for CSU) and PsO were collected in the National Health 
and Wellness Survey (NHWS). Outcome measures included the Work Productivity 
and Activity Impairment (WPAI) questionnaire and self-reported healthcare use in 
prior 6 months. Generalized linear models with different link functions were used 
to compare patients with CU vs. overall PsO (includes all severity levels) and CU 
vs. moderate-severe-PsO, controlling for patient characteristics. Results: Study 
included 769 CU patients and 7,857 PsO patients (26.9% moderate-severe). CU 
patients reported non-significant higher rate ratio (RR) of absenteeism (RR= 1.31), 
presenteeism (1.15) and overall work impairment (1.15) than overall PsO, however, 
activity impairment was significantly higher among CU patients (1.21; p< 0.05). 
The rates of work and activity impairment were similar between CU and moder-
ate-severe-PsO patients (RR: absenteeism; 0.99, presenteeism; 0.97, overall work 
impairment; 0.97 and activity impairment; 1.08) (all p= NS). Rate of healthcare vis-
its were higher among CU than overall PsO (RR: HCP visits; 1.16, ER visits; 2.13, 
Hospitalizations; 1.94, all p< 0.001) and also than moderate-severe-PsO patients (RR: 
HCP visits;1.07, ER visits;1.77, Hospitalizations;1.47, all p< 0.001). ConClusions: 
Patients with CU and PsO report a similar negative impact on work ability. Compared 
to overall PsO patients with CU have a significantly higher impact on daily activities 
and non-significant higher impairment on work components. The impact on work 
and activities is similar among CU and moderate-severe PsO. CU patients report 
significantly higher use of medical resources than Pso.
objeCtives: To estimate the incremental cost-utility ratio (ICUR) for ingenol mebu-
tate vs diclofenac 3% for actinic keratosis (AK) patient’s treatment on the face and 
scalp, and trunk and extremities, in Spain. Methods: A hypothetical cohort of 73 
aged AK patients was simulated for a 5-year time horizon with a Markov model. 
Duration of treatments was 3 days (face-scalp) and 2 days (trunk-extremities) for 
ingenol mebutate and 90 days (face-scalp and trunk-extremities) for diclofenac. 
Total clearances rates (42.24% and 34.07% for ingenol mebutate and 24.64% and 
25.07% for diclofenac on face-scalp and on trunk-extremities, respectively) obtained 
from indirect mixed comparisons and adjusted according compliance were used 
as effectiveness measure. Annual recurrence rate (20%) derived from literature. 
The perspective of the Spanish National Health System (NHS) was choosen. Total 
cost estimation (€ ,2015) included: pharmaceutical cost (retail price VAT included 
with mandatory deduction), and dermatology visits cost (for adverse events and 
disease management).A 3% annual discount rate was applied for costs and out-
comes. Utilities values (0.986 for AK and 1.00 for clearance) were used to derive 
quality-adjusted-life years (QALY). Several sensitivity analyses were performed to 
test model robustness. Results: Ingenol mebutate showed higher effectiveness, 
with 0.192 incremental clearances and 0.011 incremental QALYs (face-scalp), and 
0.129 incremental clearances and 0.007 incremental QALYs (trunk-extremities) 
compared to diclofenac. Total costs accounted were € 551.50 and € 622.27 (46% drug 
cost) for ingenol mebutate, compared to € 849.11 and € 844.93 (54% drug cost) for 
diclofenac (for face-scalp and trunk-extremities, respectively). Ingenol mebutate 
versus diclofenac 3% was dominant on face-scalp and trunk-extremities AK treat-
ment. Further, ingenol mebutate remained a dominant option in 96% (face-scalp) 
and 91% (trunk-extremities) of the 1,000 MonteCarlo simulations of probabilistic 
sensitivity analysis. ConClusions: Ingenol mebutate was a dominant strategy for 
Spanish NHS, compared to diclofenac 3%, for treatment of patients with AK both, 
face-scalp and trunk-extremities.
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objeCtives: Secukinumab (SEC300), an IL-17A antibody, was recently approved as 
highly effective therapy for moderate-to-severe plaque psoriasis (PSO). We examined 
the cost-effectiveness of SEC300 compared against other systemic biologic drugs: 
adalimumab (ADA), etanercept (ETA), infliximab (INF), ustekinumab (UST) 45 and 
90 mg, and standard of care (SOC - cyclosporine and methotrexate) for plaque pso-
riasis, in the Italian National Health System (NHS) setting. Methods: A previous 
cost-effectiveness model was adapted to the Italian healthcare setting. The model 
was designed to consider the clinical benefits, resource use and costs related to 
SEC300. A decision tree reflecting response to treatment (PASI change < 50, 50-75, 
75-90, 90-99, 100) fed into a long-term Markov model with health states related 
to treatment continuation, dropout, and death. Clinical data (PASI change scores, 
percentage of adverse events, discontinuation rate) and utility scores were derived 
from clinical trials as well as from published evidence on Italian patients. The per-
spective of the model is the Italian NHS, therefore only direct medical costs (drug 
prices, inpatient and outpatient hospital tariffs, etc.) were taken in account. Both 
costs and benefits were discounted at 3% according to Italian National Guidelines 
for Health Economics Evaluations. Incremental cost-effectiveness ratios (ICERs) 
were calculated. Results: At 10 years, SEC300 is a dominant (less costly and more 
effective) option compared with UST45 and UST90. It is a cost-effective option – with 
a threshold < € 50,000/QALY gained as per National Health Economics Evaluation 
Guidelines – vs. ADA, IFN, ETA, and SOC with an ICERs of € 37,252, € 48,949, € 21,943 
and € 41,896, respectively. The sensitivity analysis demonstrated the robustness of 
model results. ConClusions: The model shows that SEC300 is a cost‐effective 
option when compared to other biologic agents and SOC currently funded by NHS 
in Italy for the treatment of moderate-to-severe plaque psoriasis.
PSS51
coSt-eFFectiveneSS analySiS oF SecukinumaB comPared to 
uStekinumaB in tHe treatment oF moderate to Severe Plaque 
PSoriaSiS in tHe czecH rePuBlic
Klimes J1, Mollon P2, Graham C3, Rajnoch J1, Dostal F1, Skalicky D1, Jordan P1, Depta J2
1Novartis, s.r.o., Prague, Czech Republic, 2Novartis Pharma AG, Basel, Switzerland, 3RTI Health 
Solutions, NC, NC, USA
objeCtives: Secukinumab (SEC), an IL-17A antibody, is a new highly effective 
therapy for moderate-to-severe plaque psoriasis (PSO). Ustekinumab (UST) is 
reimbursed in the Czech Republic under the condition of ≥ PASI50 response at 
week 16. We estimated the cost effectiveness of SEC vs. UST based on differ-
ent PASI response (dis/continuation) criteria; PASI≥ 75 for SEC and PASI≥ 50 for 
UST. Methods: A decision tree reflecting response to treatment (PASI change 
< 50, 50-75, 75-90, 90-99, 100) fed into a long-term Markov model with health states 
related to treatment continuation, dropout, and death. Responders at week 16 
(defined as PASI≥ 75 for SEC, PASI≥ 50 for UST) continued on biologic treatment. 
Non-responders and drop-outs were switched to standard-of-care (MTX, CyA, 
emollients). A health-care system perspective with 3% discount rate was adopted. 
Dosing schedule for maintenance treatment for SEC and UST as 12.0 and 4.35 
doses per year was calculated. Baseline patient characteristics and efficacy data 
were derived from the CLEAR study, a head-to-head 52-week superiority trial (SEC 
300 mg vs. UST 45/90 mg). Long-term treatment resistance and dropout were 
modelled by assuming a 20% annual discontinuation rate. Utility weights for each 
health state were calculated from EQ-5D measures from the SEC clinical pro-
gram. Results: With a 10-year time horizon, SEC treatment gains 0.05 QALYs and 
0.80 years in PASI≥ 90 with € 144 in cost savings vs. UST, reflecting dominance of 
SEC vs. UST. Absolute (discounted) QALYs, years in ≥ PASI90 and costs (discounted) 
